Lawrence A. Kenyon, Executive Vice President, CFO and Interim CEO About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with ...

Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...

Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $2.19 which represents a decrease of $-0.11 or -4.78% from the prior close of $2.3. The stock opened at $2.13 and touched a low ...

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study evaluating ONS-5010 (Lytenava) to treat patients with wet age-related ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat reports ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company that focuses on retinal diseases saw its stock price upped 18.24% on Friday after its financial results for fiscal years 2024 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...